first
patient
randomized
phase
dissolve
clinical
program
chronic
refractory
gout
stockholm
sweden
watertown
globe
newswire
swedish
orphan
biovitrum
ab
publ
sto
sobi
selecta
biosciences
nasdaq
selb
today
announced
commencement
phase
clinical
program
chronic
refractory
gout
randomization
first
patient
study
pleased
commenced
phase
dissolve
program
evaluating
two
phase
studies
said
carsten
brunn
president
ceo
selecta
serves
important
validation
selecta
immtortm
platform
proud
advanced
clinical
studies
partnership
sobi
look
forward
enrolling
patients
studies
continuing
evaluate
new
treatment
option
patients
chronic
refractory
guido
oelkers
president
ceo
sobi
added
potential
significantly
improve
outcomes
patients
chronic
refractory
gout
proud
taken
next
step
towards
making
therapy
accessible
patients
unable
maintain
treatment
currently
available
sobi
selecta
responsible
development
regulatory
commercial
activities
markets
outside
china
phase
program
run
selecta
funded
sobi
topline
data
phase
clinical
program
expected
second
half
biologics
license
application
bla
filing
us
fda
expected
commencement
phase
program
sobi
pay
milestone
usd
selecta
dissolve
clinical
program
phase
dissolve
clinical
program
consists
two
trials
titled
randomized
study
patients
gout
refractory
conventional
therapy
evaluated
two
doses
immtor
mg
kg
mg
kg
one
dose
pegadricase
mg
kg
studies
trial
aim
enroll
patients
dose
level
placebo
dissolve
safety
efficacy
evaluated
six
months
extension
dissolve
ii
assess
safety
efficacy
time
point
extension
primary
endpoint
studies
serum
uric
acid
levels
sua
six
months
measure
disease
severity
chronic
refractory
gout
secondary
endpoints
include
tender
swollen
joint
counts
tophus
burden
patient
reported
outcomes
activity
limitation
quality
life
gout
flare
incidence
details
study
visit
novel
combination
product
candidate
designed
sustain
control
serum
uric
acid
sua
levels
patients
chronic
refractory
gout
potentially
reducing
harmful
tissue
urate
deposits
left
untreated
lead
debilitating
gout
flares
joint
consists
pegadricase
selecta
proprietary
pegylated
uricase
immtor
designed
mitigate
formation
antibodies
adas
adas
develop
due
unwanted
immune
responses
biologic
medicines
may
reduce
efficacy
tolerability
remains
issue
across
multiple
therapeutic
modalities
disease
states
including
chronic
refractory
gout
chronic
refractory
gout
gout
common
form
inflammatory
arthritis
million
patients
united
states
diagnosed
gout
caused
high
levels
uric
acid
body
accumulate
around
joints
tissues
result
flares
cause
intense
pain
approximately
patients
united
states
suffer
chronic
refractory
gout
painful
debilitating
condition
patients
able
get
sua
levels
mg
dl
therefore
several
flares
per
year
develop
nodular
masses
uric
acid
crystals
known
elevated
sua
levels
associated
diseases
heart
vascular
system
metabolism
kidney
selecta
biosciences
selecta
biosciences
nasdaq
selb
leveraging
clinically
validated
platform
develop
tolerogenic
therapies
selectively
mitigate
unwanted
immune
responses
proven
ability
induce
tolerance
highly
immunogenic
proteins
immtor
potential
amplify
efficacy
biologic
therapies
including
redosing
gene
therapies
well
restore
body
natural
autoimmune
diseases
company
first
program
aimed
addressing
immunogenicity
aav
gene
therapies
expected
enter
clinical
trials
early
partnership
askbio
treatment
methylmalonic
acidemia
mma
rare
metabolic
disorder
program
focused
addressing
iga
nephropathy
driven
immtor
therapeutic
enzyme
also
development
among
additional
product
candidates
selecta
recently
licensed
phase
clinical
program
chronic
refractory
gout
sobi
information
please
visit
sobi
sobi
specialized
international
biopharmaceutical
company
transforming
lives
people
rare
diseases
sobi
providing
sustainable
access
innovative
therapies
areas
hematology
immunology
specialty
care
indications
today
sobi
employs
approximately
people
across
europe
north
america
middle
east
russia
north
africa
sobi
revenue
amounted
sek
billion
sobi
share
sto
sobi
listed
nasdaq
stockholm
find
information
sobi
selecta
statements
statements
press
release
future
expectations
plans
prospects
selecta
biosciences
company
including
without
limitation
company
actions
regarding
monitoring
assessment
company
operations
clinical
trials
manufacturing
ability
company
immtor
platform
unlock
full
potential
biologic
therapies
potential
treatment
applications
product
candidates
utilizing
immtor
platform
areas
enzyme
therapy
gene
therapy
novelty
treatment
paradigms
sarepta
able
develop
combination
company
immtor
technology
potential
therapies
developed
sarepta
combination
company
immtor
technology
fulfill
unmet
medical
needs
company
plan
apply
immtor
technology
platform
range
biologics
rare
serious
diseases
clinical
development
commercialization
regulatory
activities
related
either
company
sobi
including
respect
anticipated
geographic
markets
anticipated
timing
planned
phase
clinical
trial
potential
market
opportunity
potential
fulfill
unmet
needs
chronic
refractory
gout
patients
including
sustained
sua
reduction
reduced
flares
repeated
monthly
dosing
well
ability
dose
longer
current
standard
care
company
sobi
commercial
plans
potential
immtor
technology
platform
generally
company
ability
grow
strategic
partnerships
sufficiency
company
cash
cash
equivalents
investments
statements
containing
words
anticipate
believe
continue
could
estimate
expect
hypothesize
intend
may
plan
potential
predict
project
target
would
similar
expressions
constitute
statements
within
meaning
private
securities
litigation
reform
act
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
limited
following
uncertainties
inherent
initiation
completion
cost
clinical
trials
including
uncertain
outcomes
effect
outbreak
company
planned
ongoing
clinical
trials
manufacturing
activities
supply
chain
operations
availability
timing
data
ongoing
future
clinical
trials
results
trials
whether
preliminary
results
particular
clinical
trial
predictive
final
results
trial
whether
results
early
clinical
trials
indicative
results
later
clinical
trials
unproven
approach
company
immtor
technology
undesirable
side
effects
company
product
candidates
reliance
third
parties
manufacture
product
candidates
conduct
clinical
trials
well
impact
outbreak
third
parties
ability
continue
operations
company
inability
maintain
existing
future
collaborations
licenses
contractual
relationships
inability
protect
proprietary
technology
intellectual
property
management
ability
perform
expected
potential
delays
regulatory
approvals
availability
funding
sufficient
foreseeable
unforeseeable
operating
expenses
capital
expenditure
requirements
company
recurring
losses
operations
negative
cash
flows
operations
raise
substantial
doubt
regarding
ability
continue
going
concern
substantial
fluctuation
price
common
stock
including
stock
market
fluctuations
occur
result
outbreak
important
factors
discussed
risk
factors
section
company
recent
quarterly
report
form
filings
company
makes
securities
exchange
commission
addition
statements
included
press
release
represent
company
views
date
publication
relied
upon
representing
views
subsequent
date
company
specifically
disclaims
intention
update
statements
included
press
release
information
please
contact
sobi
paula
treutiger
head
communication
investor
relations
linda
holmstr√∂m
corporate
communication
investor
relations
selecta
investors
lee
stern
solebury
trout
lstern
media
meredith
sosulski
lifesci
communications
llc
msosulski
https
ix
archives
edgar
data
kishimoto
tk
development
immtor
tolerogenic
nanoparticles
mitigation
antibodies
front
immunol
may
doi
